Felipe K. Hurtado

Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers

Julien P. N. Papillon, Katsumasa Nakajima, Christopher D. Adair et al. · Journal of Medicinal Chemistry · 2018 · 237 citations · Full text

Medicine, Cancer Biology, Oncology +11

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto Chiappori, Ben Creelan, Tawee Tanvetyanon et al. · Clinical Cancer Research · 2022 · 69 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

The structure of a prokaryotic viral envelope protein expands the landscape of membrane fusion proteins

Kamel El Omari, Sai Li, Abhay Kotecha et al. · Nature Communications · 2019 · 49 citations · Full text

Life Sciences, Biology, Microbiology +17

Phase I/II study of the A2AR antagonist NIR178 (PBF-509), an oral immunotherapy, in patients (pts) with advanced NSCLC.

Alberto Chiappori, Charles C. Williams, Ben Creelan et al. · Journal of Clinical Oncology · 2018 · 47 citations

Medicine, Oncology, Pharmacology +17

Results of the ASCEND-7 phase II study evaluating ALK inhibitor (ALKi) ceritinib in patients (pts) with ALK+ non-small cell lung cancer (NSCLC) metastatic to the brain

Laura Q.M. Chow, Fabrice Barlési, Erin M. Bertino et al. · Annals of Oncology · 2019 · 42 citations

Medicine, Oncology, Pharmacology +16